Obesity-Focused Zafgen Raises Zaftig Series B

Three years after its launch, Zafgen emerges from stealth mode with a new CEO and another $14 million in funding.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet